已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer: a single-center retrospective study.

医学 内科学 化疗 不利影响 卵巢癌 回顾性队列研究 病历 肿瘤科 联合疗法 单中心 临床疗效 癌症 外科 胃肠病学
作者
Yue Wu,Ping Li,Yaodong Zhu,Fengli Zhang,Li Su,Yingquan Ye,Yi Huang,Mei Zhang
出处
期刊:PubMed [National Institutes of Health]
卷期号:15 (3): 1973-1981 被引量:2
链接
标识
摘要

To evaluate the clinical efficacy of mono-anlotinib therapy by itself or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer (PROC).The clinical data of 35 patients with platinum-resistant recurrent ovarian cancer admitted to the First Affiliated Hospital of Anhui Medical University from March 2019 to July 2020 were retrospectively analyzed. All the patients received anlotinib mono- or combined chemotherapy. The effectiveness and adverse events (AEs) were analyzed by RECIST1.1 and CTCAE5.0.In the 35 patients, the median follow-up was 9.80 (95% CI: 3.83-15.77) months. The median progression free survival (mPFS) achieved 6.50 (95% CI: 2.02-10.98) months, the objective response rate (ORR) achieved 17.14%, and disease control rate (DCR) achieved 60.00%. ORR and DCR were 12.50% and 25.0% for monotherapy, 18.52% and 70.37% for combined chemotherapy. The PFS of combined chemotherapy was longer than that of monotherapy (log-rank P = 0.003). thirty-four patients (97.14%) were in a third-line therapy or above, and their ORR and DCR were 14.71% and 58.82%, respectively. Two patients discontinued treatment because of intolerable AEs. No cases of grade 4-5 AEs have been reported.Anlotinib had promising effectiveness and tolerable safety in patients with PROC, even in patients who accepted anlotinib as a third-line or above therapy or with a history of other antiangiogenic drugs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
oneming发布了新的文献求助10
1秒前
123的应助被科研通管家采纳,获得30
1秒前
尘埃落定发布了新的文献求助10
1秒前
李爱国的应助被科研通管家采纳,获得30
1秒前
香蕉觅云的应助被科研通管家采纳,获得10
2秒前
领导范儿的应助被科研通管家采纳,获得10
2秒前
极限001的应助被科研通管家采纳,获得50
2秒前
2秒前
传奇3的应助被科研通管家采纳,获得10
2秒前
今后的应助被科研通管家采纳,获得10
2秒前
CipherSage的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
英姑的应助被科研通管家采纳,获得10
3秒前
3秒前
3秒前
3秒前
4秒前
某某发布了新的文献求助10
4秒前
个性向卉发布了新的文献求助10
5秒前
xx完成签到 ,获得积分10
5秒前
传奇3的应助被坚定的采波采纳,获得10
6秒前
ZB完成签到 ,获得积分10
6秒前
昏睡的山柳完成签到 ,获得积分10
7秒前
顷梦完成签到,获得积分10
7秒前
7秒前
8秒前
9秒前
keccet完成签到,获得积分20
9秒前
9秒前
隐形曼青的应助被Lu采纳,获得10
10秒前
11秒前
凌凌冬关注了科研通微信公众号
11秒前
hhhh完成签到,获得积分10
12秒前
12秒前
zhang完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184595
求助须知:如何正确求助?哪些是违规求助? 9573554
关于积分的说明 21832227
捐赠科研通 7781812
什么是DOI,文献DOI怎么找? 3434399
关于科研通互助平台的介绍 2558490
邀请新用户注册赠送积分活动 2480994